Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:6171 |
Name | uterine carcinosarcoma |
Definition | A uterine body mixed cancer that has_material_basis_in both endometrial carcinoma and sarcoma. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer reproductive organ cancer female reproductive organ cancer uterine cancer uterine corpus cancer uterine body mixed cancer uterine carcinosarcoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
FGFR1 amp | Pazopanib | uterine carcinosarcoma | predicted - sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02203760 | Phase II | Pazopanib Gemcitabine + Pazopanib | Pazopanib vs. Pazopanib Plus Gemcitabine (PazoDoble) | Active, not recruiting | DEU | 0 |
NCT02963831 | Phase Ib/II | Durvalumab + ONCOS-102 | A Phase 1/2 Study to Investigate the Safety, Biologic and Anti-tumor Activity of ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies | Completed | USA | 0 |
NCT03241745 | Phase II | Nivolumab | A Study of Nivolumab in Selected Uterine Cancer Patients | Completed | USA | 0 |
NCT03485729 | Phase II | ONC201 | ONC201 in Recurrent or Metastatic Type II Endometrial Cancer Endometrial Cancer | Active, not recruiting | USA | 0 |
NCT03555422 | Phase III | Selinexor | Maintenance With Selinexor/Placebo After Combination Chemotherapy in Endometrial Cancer [SIENDO] (SIENDO) | Active, not recruiting | USA | ITA | ISR | GRC | ESP | DEU | CZE | CAN | BEL | 1 |
NCT03603184 | Phase III | Atezolizumab + Carboplatin + Paclitaxel Carboplatin + Paclitaxel | Atezolizumab Trial in Endometrial Cancer - AtTEnd (AtTEnd) | Active, not recruiting | NZL | ITA | GBR | ESP | DEU | CHE | AUT | AUS | 3 |
NCT03651206 | Phase II | Paclitaxel + Pegylated liposomal doxorubicin + Topotecan Doxorubicin + Gemcitabine + Paclitaxel Niraparib Dostarlimab-gxly + Niraparib | Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib (ROCSAN) | Active, not recruiting | FRA | 0 |
NCT03668340 | Phase II | Adavosertib | AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma | Active, not recruiting | USA | 0 |
NCT03675893 | Phase II | Abemaciclib + LY3023414 Abemaciclib + Letrozole Abemaciclib + Letrozole + Metformin Abemaciclib + Letrozole + LY3023414 Abemaciclib + Letrozole + Zotatifin | RESOLVE: Abemaciclib + Letrozole +/- Metformin or Zotatifin in Endometrial or Low-Grade Serous Ovarian Cancer | Active, not recruiting | USA | 0 |
NCT03694262 | Phase II | Atezolizumab + Bevacizumab + Rucaparib | The EndoBARR Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib) (EndoBARR) | Completed | USA | 0 |
NCT03832361 | Phase II | Mirvetuximab Soravtansine | Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-alpha Positive Endometrial Cancer | Recruiting | USA | 0 |
NCT04106414 | Phase II | Nivolumab Linrodostat + Nivolumab | Study of BMS-986205 and Nivolumab in Endometrial Cancer or Endometrial Carcinosarcoma That Has Not Responded to Treatment | Active, not recruiting | USA | 0 |
NCT04235101 | Phase I | Niraparib + Trastuzumab Duocarmazine | Phase I Study of SYD985 With Niraparib in Patients With Solid Tumors | Completed | NLD | GBR | BEL | 0 |
NCT04513665 | Phase II | ZW25 | ZW25 in Women With Endometrial Cancers | Completed | USA | 0 |
NCT04634877 | Phase III | Carboplatin + Paclitaxel Cisplatin + Paclitaxel Carboplatin + Docetaxel Cisplatin + Paclitaxel + Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab Cisplatin + Docetaxel + Pembrolizumab Cisplatin + Docetaxel Carboplatin + Docetaxel + Pembrolizumab | Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053) | Active, not recruiting | USA | TUR | SWE | POL | NOR | ITA | ISR | GRC | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CAN | BEL | AUT | ARG | 9 |
NCT04906382 | Phase I | Carboplatin + Paclitaxel + Tislelizumab | Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer | Terminated | USA | 0 |
NCT04969887 | Phase II | Ipilimumab + Nivolumab | Combination Immunotherapy in Rare Cancers Under InvesTigation (MOST-CIRCUIT) | Active, not recruiting | NZL | AUS | 0 |
NCT05147558 | Phase II | Lenvatinib + Pembrolizumab | A Study of Pembrolizumab With Lenvatinib in Women With Advanced Uterine Carcinosarcoma | Recruiting | USA | 0 |
NCT05156268 | Phase II | Olaparib + Pembrolizumab | A Study of Pembrolizumab and Olaparib in People With Endometrial Cancer or Endometrial Carcinosarcoma | Active, not recruiting | USA | 0 |
NCT05173987 | Phase III | Cisplatin + Docetaxel Carboplatin + Docetaxel Carboplatin + Paclitaxel Cisplatin + Paclitaxel Pembrolizumab | Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15) | Active, not recruiting | USA | TUR | SWE | POL | NZL | NOR | NLD | ITA | ISR | IRL | HUN | GBR | FIN | ESP | DNK | DEU | CZE | CAN | BRA | BEL | AUS | 6 |
NCT05229601 | Phase I | HFB301001 | A Study of HFB301001 in Adult Patients With Advanced Solid Tumors | Active, not recruiting | USA | ESP | 0 |
NCT05255653 | Phase II | Olaparib Medroxyprogesterone Carboplatin Megestrol acetate Paclitaxel Cisplatin Durvalumab | Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features (RAINBO) | Recruiting | NLD | GBR | FRA | CAN | 0 |
NCT05256225 | Phase II | Carboplatin + Paclitaxel + Pertuzumab/trastuzumab/hyaluronidase-zzxf Carboplatin + Paclitaxel Carboplatin + Paclitaxel Trevatide + trastuzumab and hyaluronidase-oysk injection | Testing the Addition of Trastuzumab or Trastuzumab/Pertuzumab to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma | Recruiting | USA | 1 |
NCT05300048 | Phase I | Serabelisib Nab-paclitaxel + Serabelisib | Combination of Serabelisib and Insulin Suppressing Diet With or Without Nab-paclitaxel in Subjects With Advanced Solid Tumors With PIK3CA Mutations | Active, not recruiting | USA | 0 |
NCT05559879 | Phase Ib/II | Cabozantinib + Dostarlimab-gxly | Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma | Recruiting | USA | 0 |
NCT05605509 | Phase II | Fluorouracil + Irinotecan + Leucovorin + RP-6306 RP-6306 + Trastuzumab Gemcitabine + RP-6306 | RP-6306 in Patients With Advanced Cancer | Recruiting | CAN | 0 |
NCT05611931 | Phase III | Selinexor | Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma (XPORT-EC-042) | Recruiting | USA | SVK | ITA | ISR | IRL | HUN | GRC | ESP | DEU | CZE | CAN | BEL | AUS | 1 |
NCT05619913 | Phase II | Eribulin Eribulin + Pembrolizumab | EPOCH: Eribulin and Pembrolizumab in Ovarian/Uterine Carcinosarcoma (EPOCH) | Recruiting | GBR | CAN | AUS | 0 |
NCT06132958 | Phase III | Paclitaxel Doxorubicin SKB264 | MK-2870 in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005) | Recruiting | USA | SWE | POL | NOR | NLD | ITA | ISR | IRL | GRC | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CHE | CAN | BRA | BEL | AUT | AUS | ARG | 8 |
NCT06172478 | Phase II | Patritumab deruxtecan | A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors | Recruiting | USA | 2 |
NCT06366347 | Phase II | Pembrolizumab Abemaciclib + Letrozole | ALPINE: Maintenance Letrozole/Abemaciclib vs Pembrolizumab | Recruiting | USA | 0 |
NCT06486441 | Phase III | Doxorubicin Paclitaxel Sacituzumab govitecan-hziy | Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26) (ASCENT-GYN-01) | Recruiting | USA | 0 |
NCT06660654 | Phase II | Raludotatug deruxtecan | A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01) | Not yet recruiting | USA | 0 |